MarketPulse

neuromodulation

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

electroCore Posts 43% Revenue Growth Despite Losses Ahead of May Conference

electroCore reports 43% Q1 2026 revenue growth to $9.6M and will present at LD Micro conference May 18, advancing its bioelectronic medicine growth narrative.
ECORrevenue growthneuromodulation
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

NeurAxis to Report Q1 2026 Results as Neuromodulation Startup Eyes Commercial Traction

NeurAxis will report Q1 2026 financial results on May 12, 2026, as the neuromodulation company continues commercializing its FDA-cleared IB-Stim technology.
NRXSmedical technologyQ1 2026 earnings
GlobeNewswire Inc.GlobeNewswire Inc.··Na

electroCore to Showcase Bioelectronic Medicine Strategy at May Summit

electroCore ($ECOR) will present at Market Movers Investor Summit on May 5, 2026, with interim leadership discussing company strategy and conducting investor meetings.
ECORcapital marketsneuromodulation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

VisionSys AI Secures $90M Strategic Investment to Accelerate Brain-Computer Interface Commercialization

VisionSys AI announces $90M strategic investment at $1.50/share to advance non-invasive BCI technology and expand AI healthcare solutions globally.
VSAstrategic investmentneuromodulation
The Motley FoolThe Motley Fool··Eric Volkman

Boston Scientific Poised for 5X Growth as Aging Demographics Drive Demand

Boston Scientific positioned to capitalize on global aging through AFib, chronic pain, and Parkinson's treatments; recent acquisitions boost stroke capabilities.
BSXPENhealthcarevaluation